MARKET

ASMB

ASMB

Assembly
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.250
+0.020
+0.62%
After Hours: 3.240 -0.01 -0.31% 19:29 09/20 EDT
OPEN
3.220
PREV CLOSE
3.230
HIGH
3.270
LOW
3.145
VOLUME
459.48K
TURNOVER
--
52 WEEK HIGH
17.54
52 WEEK LOW
3.090
MARKET CAP
146.16M
P/E (TTM)
-1.3264
1D
5D
1M
3M
1Y
5Y
HC Wainwright & Co. Initiates Coverage On Assembly Biosciences with Neutral Rating, Announces Price Target of $3.5
HC Wainwright & Co. analyst Ed Arce initiates coverage on Assembly Biosciences (NASDAQ:ASMB) with a Neutral rating and announces Price Target of $3.5.
Benzinga · 09/13 10:43
--HC Wainwright Starts Assembly Biosciences at Neutral with $3.50 Price Target
MT Newswires · 09/13 09:26
Hot Stocks: Grocery store highs; PWR jumps on M&A; ASAN rises on earnings; drug setback for ASMB
Food manufacturers and general-merchandise retailers have faced challenges recently, with supply-chain disruptions complicating their ability to provide forecasts for the tail end of the year. But what about retailers who
Seekingalpha · 09/02 21:26
Sector Update: Health Care Stocks Continue to Gain Steam Throughout Thursday Trading
MT Newswires · 09/02 16:00
Innate Pharma, Tiziana Life Sciences leads healthcare gainers; Assembly Biosciences, Phreesia among major losers
Gainers: Innate Pharma (NASDAQ:IPHA) +32%, Tiziana Life Sciences (NASDAQ:TLSA) +16%, Verrica Pharmaceuticals (NASDAQ:VRCA) +12%, NeuroBo Pharmaceuticals (NASDAQ:NRBO) +12%, Scopus BioPharma (NASDAQ:SCPS) +11%. Losers: Assembly Biosciences (NASDAQ:ASMB) -17...
Seekingalpha · 09/02 15:07
Mid-Morning Market Update: Markets Open Higher; Hormel Foods Cuts Earnings Outlook
Following the market opening Thursday, the Dow traded up 0.18% to 35,377.03 while the NASDAQ rose 0.23% to 15,345.05. The S&P also rose, gaining 0.27% to 4,536.45.
Benzinga · 09/02 14:18
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1)
Benzinga · 09/02 12:19
28 Stocks Moving in Thursday's Pre-Market Session
Gainers Focus Universal Inc. (NASDAQ: FCUV) rose 39.7% to $26.93 in pre-market trading after jumping 278% on Wednesday. Focus Universal recently priced 2 million shares at $5 per share to raise $10 million for its initial public offering on the Nasdaq.
Benzinga · 09/02 11:06
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ASMB. Analyze the recent business situations of Assembly through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ASMB stock price target is 9.71 with a high estimate of 15.00 and a low estimate of 3.500.
EPS
Institutional Holdings
Institutions: 137
Institutional Holdings: 29.14M
% Owned: 64.79%
Shares Outstanding: 44.97M
TypeInstitutionsShares
Increased
29
3.31M
New
15
487.44K
Decreased
36
4.11M
Sold Out
30
1.33M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.35%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Non-Executive Chairman/Independent Director
William Ringo
President/Chief Executive Officer/Director
John McHutchison
Chief Financial Officer
Michael Samar
Chief Operating Officer
Jason Okazaki
Senior Vice President
Nicole White
Chief Scientific Officer
William Delaney
Other
Luisa Stamm
Director
Lisa Johnson-pratt
Independent Director
Anthony Altig
Independent Director
Gina Consylman
Independent Director
Richard DiMarchi
Independent Director
Myron Holubiak
Independent Director
Michael Houghton
Independent Director
Susan Mahony
No Data
About ASMB
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.

Webull offers kinds of Assembly Biosciences Inc stock information, including NASDAQ:ASMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASMB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ASMB stock methods without spending real money on the virtual paper trading platform.